# BNH Investment

> BNH Investment is a VC fund in Seoul backing Biotechnology and Pharmaceutical. See 39 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 39
- Last investment: Mar 2026
- Lead investor: 10%
- Last updated: Aug 2026
- Website: http://bnhinv.com

BNH Investment is an investment company for bio and healthcare sectors.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7k–$9.3M |
| Series B | $7.3M–$20M |
| Series C | $8.2M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 19 | 49% |
| Pharmaceutical | 10 | 26% |
| Medical | 8 | 21% |
| Health Care | 8 | 21% |
| Software | 5 | 13% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 11 | 28% |
| Series A | 10 | 26% |
| Series C | 6 | 15% |
| Funding Round | 4 | 10% |
| Venture - Series Unknown | 4 | 10% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LabInCube | LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials. | $9.8M | Series B | Mar 18, 2026 |  |
| Mustbio | MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. | $23.3M | Series C | Mar 13, 2026 |  |
| ENCell | ENCell is a biotech company that develops and manufactures biopharmaceuticals. | $15.3M | Post-IPO Debt | Dec 04, 2025 |  |
| Portrai | Portrai is a biotechnology research company utilizing AI in spatial transcriptomics to improve biopsy quality. The company specializes in developing highly accurate artificial intelligence technology to analyze spatial transcriptomics results. This enables doctors to efficiently examine a patient's illness by analyzing tissue samples withprecision. | $9.9M | Series B | Dec 02, 2025 |  |
| Plcoskin | Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that iscommonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds.Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds.Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Youlief is available in the US, Europe, Taiwan, Singapore and Japan. | $10.1M | Series C | Oct 27, 2025 |  |
| Pinot Bio | Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments. | $9.1M |  | Oct 27, 2025 |  |
| MediMabBio | MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M | Series B | Oct 24, 2025 |  |
| Oncosoft | Oncosoft develops software solutions with a focus on anti-cancer treatment. Their offerings include an Oncology Information Management Solution (OIMS) and artificial intelligence-based technologies for radiologists. The software aids in the detection of cancer, contributing to the medical community efforts in precision cancer therapy. | $8.2M | Series B | Sep 23, 2024 |  |
| Bazbiomedic | Bazbiomedic is a global innovation company, manufacturer of drug delivery devices intended to improve the healthcare system. Bazbiomedic a needle-free drug delivery device capable of controlling injection depth and volume. | $7.3M | Series B | May 10, 2024 |  |
| LabInCube | LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials. | $3.8M | Series A | Apr 02, 2024 |  |

10 of 39 investments shown.

## Co-investors
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 10 deals together
- [Premier Partners](https://shizune.co/investors/profile/premier-partners) — VC Fund, 9 deals together
- [HB Investment](https://shizune.co/investors/profile/hb-investment) — VC Fund, 5 deals together
- [IMM Investment](https://shizune.co/investors/profile/imm-investment) — VC Fund, 5 deals together
- [Union Investment Partners](https://shizune.co/investors/profile/union-investment-partners) — VC Fund, 5 deals together
- [Aju IB Investment](https://shizune.co/investors/profile/aju-ib-investment) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)
- [Biotech Investors in South Korea](https://shizune.co/investors/biotech-investors-south-korea)
- [Biotech VC Funds in South Korea](https://shizune.co/investors/biotech-vc-funds-south-korea)
- [Biotechnology Investors in South Korea](https://shizune.co/investors/biotechnology-investors-south-korea)
- [Biotechnology VC Funds in South Korea](https://shizune.co/investors/biotechnology-vc-funds-south-korea)

## FAQ

### What does BNH Investment invest in?

BNH Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series A stage. Most of the 39 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BNH Investment's check size?

BNH Investment typically joins rounds of $7k–$9.3M at Series A, $7.3M–$20M at Series B and $8.2M–$23M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BNH Investment participates in.

### When did BNH Investment last invest?

The most recent investment recorded for BNH Investment closed in Mar 2026. Shizune tracks 39 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co